Li Liang Cheng, Sheng Jian Rong, Mulherkar Nirupama, Prabhakar Bellur S, Meriggioli Matthew N
Department of Neurology, University of Illinois at Chicago, Chicago, Illinois 60523, USA.
Cancer Res. 2008 Sep 15;68(18):7352-61. doi: 10.1158/0008-5472.CAN-07-6311.
The IG20 gene undergoes alternative splicing resulting in the differential expression of six putative splice variants. Four of these (IG20pa, MADD, IG20-SV2, and DENN-SV) are expressed in virtually all human tissues. However, investigations examining alternative splicing of the IG20 gene to date have been largely limited to nonneural malignant and nonmalignant cells. In this study, we investigated the expression of alternative splice isoforms of the IG20 gene in human neuroblastoma cells. We found that six IG20 splice variants (IG20-SVs) were expressed in two human neuroblastoma cell lines (SK-N-SH and SH-SY5Y), highlighted by the expression of two unique splice isoforms (i.e., KIAA0358 and IG20-SV4). Similarly, we found enriched expression of these two IG20-SVs in human neural tissues derived from cerebral cortex, hippocampus, and, to a lesser extent, spinal cord. Using gain-of-function studies and siRNA technology, we determined that these "neural-enriched isoforms" exerted significant and contrasting effects on vulnerability to apoptosis in neuroblastoma cells. Specifically, expression of KIAA0358 exerted a potent antiapoptotic effect in both the SK-N-SH and SH-SY5Y neuroblastoma cell lines, whereas expression of IG20-SV4 had proapoptotic effects directly related to the activation of caspase-8 in these cells, which have minimal or absent constitutive caspase-8 expression. These data indicate that the pattern of expression of these neural-enriched IG20-SVs regulates the expression and activation of caspase-8 in certain neuroblastoma cells, and that manipulation of IG20-SV expression pattern may represent a potent therapeutic strategy in the therapy of neuroblastoma and perhaps other cancers.
IG20基因经历可变剪接,导致6种假定的剪接变体差异表达。其中4种(IG20pa、MADD、IG20-SV2和DENN-SV)几乎在所有人体组织中均有表达。然而,迄今为止,对IG20基因可变剪接的研究主要局限于非神经恶性和非恶性细胞。在本研究中,我们调查了IG20基因可变剪接异构体在人神经母细胞瘤细胞中的表达。我们发现6种IG20剪接变体(IG20-SV)在两个人神经母细胞瘤细胞系(SK-N-SH和SH-SY5Y)中表达,两种独特的剪接异构体(即KIAA0358和IG20-SV4)的表达尤为突出。同样,我们发现这两种IG20-SV在源自大脑皮层、海马体以及程度较轻的脊髓的人神经组织中表达丰富。通过功能获得性研究和小干扰RNA技术,我们确定这些“神经组织富集异构体”对神经母细胞瘤细胞的凋亡易感性产生了显著且相反的影响。具体而言,KIAA0358的表达在SK-N-SH和SH-SY5Y神经母细胞瘤细胞系中均发挥了强大的抗凋亡作用,而IG20-SV4的表达具有促凋亡作用,这与这些细胞中半胱天冬酶-8的激活直接相关,这些细胞中半胱天冬酶-8的组成型表达极少或不存在。这些数据表明,这些神经组织富集的IG20-SV的表达模式调节了某些神经母细胞瘤细胞中半胱天冬酶-8的表达和激活,并且操纵IG20-SV的表达模式可能代表了神经母细胞瘤以及或许其他癌症治疗中的一种有效治疗策略。